% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • zwerp2000 zwerp2000 Jan 8, 2013 12:40 PM Flag

    Aptuit and Aegerion sign commercial API supply agreement

    Aptuit and Aegerion sign commercial API supply agreement
    Stuart Needleman, President and CEOO, Aptuit, announced that Aptuit and Aegerion Pharmaceuticals (AEGR), Cambridge, Massachusetts, have signed a long-term supply agreement for commercial quantities of the active pharmaceutical ingredient lomitapide. Lomitapide is Aegerion's orphan drug that is targeted to the treatment of a rare disease caused by a genetic disorder. The drug received NDA approval in December of 2012 and is expected to be launched commercially in January of 2013. Previously, Aptuit scientists had established the chemistry for lomitapide, developed and validated its analytical methods, delivered solid state form control and crystallization R&D, and supplied registration ba tches of material. Post-launch, Aptuit will continue to supply commercial quantities of lomitapide to Aegerion.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.21+0.02(+0.91%)Oct 21 4:00 PMEDT